Compare Cronos Group Inc (CRON) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Cronos Group Inc trades at $2.76 (market cap $1.02B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.91. The key difference: Cronos Group Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| CRON | YMAG | |
|---|---|---|
Market Cap | $1.02B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $3.27 | $15.98 |
52-Week Low | $1.95 | $11.00 |
Enterprise Value | $203.29M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
YMAG trades at $11.70, down 0.93% on the day, with technical indicators showing a neutral overall signal. The ETF has demonstrated consistent weekly dividend distributions throughout 2026, with payouts ranging from $0.07 to $0.40 per share. Recent news highlights YMAG's strategy of bundling Magnificent Seven exposure through option income ETFs, though some analysts express concerns about NAV decay and limited upside potential.
The outlook for YMAG hinges on its ability to generate sustainable option income while managing the trade-off between yield and capital appreciation. Key risks include high expense ratios, underperformance during strong bull markets, and dependence on volatility premiums. Institutional interest appears mixed, with the fund's appeal concentrated among income-focused investors seeking Magnificent Seven exposure with enhanced yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
